1 |
中国心血管健康与疾病报告编写组.中国心血管健康与疾病报告2021概要[J].中国循环杂志,2022,37(6):553-578.
|
2 |
LANDRY N M, COHEN S, DIXON I M C. Periostin in cardiovascular disease and development: a tale of two distinct roles[J/OL]. Basic. Res. Cardiol., 2018, 113(1): 1[2023-06-02]. .
|
3 |
KII I. Practical application of periostin as a biomarker for pathological conditions[J]. Adv. Exp. Med. Biol., 2019, 1132: 195-204.
|
4 |
YANG L, GUO T, CHEN Y, et al.. The multiple roles of periostin in non-neoplastic disease[J/OL]. Cells, 2022, 12(1): 50[2023-06-09]. .
|
5 |
BJÖRKEGREN J L M, LUSIS A J. Atherosclerosis: recent developments[J]. Cell, 2022, 185(10): 1630-1645.
|
6 |
CAO L, ZHANG Z, LI Y, et al.. LncRNA H19/miR-let-7 axis participates in the regulation of ox-LDL-induced endothelial cell injury via targeting periostin[J]. Int. Immunopharmacol., 2019, 72: 496-503.
|
7 |
SINGH S, TORZEWSKI M. Fibroblasts and their pathological functions in the fibrosis of aortic valve sclerosis and atherosclerosis[J/OL]. Biomolecules, 2019, 9(9): 472[2023-06-03]. .
|
8 |
WANG Z, LI G, LI M, et al.. Periostin contributes to the adventitial remodeling of atherosclerosis by activating adventitial fibroblasts[J]. Atheroscler Plus., 2022, 50: 57-64.
|
9 |
GAO F, BAI R, QIN W, et al.. Angiotensin Ⅱ induces the expression of periostin to promote foam cell formation in oxLDL-treated macrophages[J]. Int. J. Cardiol., 2022, 347: 46-53.
|
10 |
PAN W, JIE W, HUANG H. Vascular calcification: molecular mechanisms and therapeutic interventions[J/OL]. MedComm., 2023, 4(1): e200[2023-03-08]. .
|
11 |
ALESUTAN I, HENZE L A, BOEHME B, et al.. Periostin augments vascular smooth muscle cell calcification via β-catenin signaling[J/OL]. Biomolecules, 2022, 12(8): 1157[2023-03-09]. .
|
12 |
SUN X, MA W, ZHU Y, et al.. Postn promotes diabetic vascular calcification by interfering with autophagic flux[J/OL]. Cell Signal., 2021, 83: 109983[2022-03-05]. .
|
13 |
ZHU Y, JI J, WANG X, et al.. Periostin promotes arterial calcification through PPARγ-related glucose metabolism reprogramming[J]. Am. J. Physiol. Heart Circ. Physiol., 2021, 320(6): 2222-2239.
|
14 |
SÖZMEN M, DEVRIM A K, KABAK Y B, et al.. The effects of periostin in a rat model of isoproterenol: mediated cardiotoxicity[J]. Cardiovasc. Toxicol., 2018, 18(2): 142-160.
|
15 |
KIM B R, JANG I H, SHIN S H, et al.. Therapeutic angiogenesis in a murine model of limb ischemia by recombinant periostin and its fasciclin I domain[J]. Biochim. Biophys. Acta, 2014, 1842(9): 1324-1332.
|
16 |
THENAPPAN T, ORMISTON M L, RYAN J J, et al.. Pulmonary arterial hypertension: pathogenesis and clinical management[J/OL]. Brit. Med. J., 2018, 360: j5492[2022-03-18]. .
|
17 |
MARTIN DE MIGUEL I, CRUZ-UTRILLA A, OLIVER E, et al.. Novel molecular mechanisms involved in the medical treatment of pulmonary arterial hypertension[J/OL]. Int. J. Mol. Sci., 2023, 24(4): 4147[2023-03-24]. .
|
18 |
YOSHIDA T, NAGAOKA T, NAGATA Y, et al.. Periostin‐related progression of different types of experimental pulmonary hypertension: a role for M2 macrophage and FGF‐2 signalling[J]. Respirology, 2022, 27(7): 529-538.
|
19 |
IMOTO K, OKADA M, YAMAWAKI H. Periostin mediates right ventricular failure through induction of inducible nitric oxide synthase expression in right ventricular fibroblasts from monocrotaline-induced pulmonary arterial hypertensive rats[J/OL]. Int. J. Mol. Sci., 2018, 20(1): 62[2023-03-23]. .
|
20 |
BRUNS D R, TATMAN P D, KALKUR R S, et al.. The right ventricular fibroblast secretome drives cardiomyocyte dedifferentiation[J/OL]. PLoS ONE, 2019, 14(8): e220573[2023-03-23]. .
|
21 |
WANG X, LI F, MA D, et al.. Periostin mediates cigarette smoke extract-induced proliferation and migration in pulmonary arterial smooth muscle cells[J]. Biomed. Pharmacother., 2016, 83: 514-520.
|
22 |
NIE X, SHEN C, TAN J, et al.. Periostin: a potential therapeutic target for pulmonary hypertension?[J]. Circ. Res., 2020, 127(9): 1138-1152.
|
23 |
FRANTZ S, HUNDERTMARK M J, SCHULZ-MENGER J, et al.. Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies[J]. Eur. Heart J., 2022, 43(27): 2549-2561.
|
24 |
LI L, ZHAO Q, KONG W. Extracellular matrix remodeling and cardiac fibrosis[J]. Matrix Biol., 2018, 68-69: 490-506.
|
25 |
KAUR H, TAKEFUJI M, NGAI C Y, et al.. Targeted ablation of periostin-expressing activated fibroblasts prevents adverse cardiac remodeling in mice[J]. Circ. Res., 2016, 118(12): 1906-1917.
|
26 |
DIXON I, LANDRY N M, RATTAN S G. Periostin reexpression in heart disease contributes to cardiac interstitial remodeling by supporting the cardiac myofibroblast phenotype[J]. Adv. Exp. Med. Biol., 2019, 1132: 35-41.
|
27 |
LIAO Y, LI G, ZHANG X, et al.. Cardiac nestin(+) mesenchymal stromal cells enhance healing of ischemic heart through periostin-mediated M2 macrophage polarization[J]. Mol. Ther., 2020, 28(3): 855-873.
|
28 |
XUE K, CHEN S, CHAI J, et al.. Upregulation of periostin through creb participates in myocardial infarction-induced myocardial fibrosis[J]. J. Cardiovasc. Pharmacol., 2022, 79(5): 687-697.
|
29 |
BRUNTON-O'SULLIVAN M M, HOLLEY A S, BIRD G K, et al.. Examining variation and temporal dynamics of extracellular matrix biomarkers following acute myocardial infarction[J]. Biomark. Med., 2022, 16(3): 147-161.
|
30 |
O'DONNELL A, YUTZEY K E. Mechanisms of heart valve development and disease[J/OL]. Development, 2020, 147(13): dev183020[2023-03-29]. .
|
31 |
DI VITO A, DONATO A, PRESTA I, et al.. Extracellular matrix in calcific aortic valve disease: architecture, dynamic and perspectives[J/OL]. Int. J. Mol. Sci., 2021, 22(2): 913[2023-06-09]. .
|
32 |
CHEEK J D, WIRRIG E E, ALFIERI C M, et al.. Differential activation of valvulogenic, chondrogenic, and osteogenic pathways in mouse models of myxomatous and calcific aortic valve disease[J]. J. Mol. Cell. Cardiol., 2012, 52(3): 689-700.
|
33 |
HAKUNO D, KIMURA N, YOSHIOKA M, et al.. Periostin advances atherosclerotic and rheumatic cardiac valve degeneration by inducing angiogenesis and MMP production in humans and rodents[J]. J. Clin. Invest., 2010, 120(7): 2292-2306.
|
34 |
BAMAN J R, PASSMAN R S. Atrial fibrillation[J/OL]. J. Am. Med. Assoc., 2021, 325(21): 2218[2023-04-01]. .
|
35 |
SOHNS C, MARROUCHE N F. Atrial fibrillation and cardiac fibrosis[J]. Eur. Heart J., 2020, 41(10): 1123-1131.
|
36 |
ROH S, KIM J Y, CHA H K, et al.. Molecular signatures of sinus node dysfunction induce structural remodeling in the right atrial tissue[J]. Mol. Cells, 2020, 43(4): 408-418.
|
37 |
FANG L, JIN H, LI M, et al.. Serum periostin as a predictor of early recurrence of atrial fibrillation after catheter ablation[J]. Heart. Vessels., 2022, 37(12): 2059-2066.
|